NSE · GRANULES.NS
Granules India Limited
₹841.15+₹3.80 (+0.45%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.93% below the high.
Loading market information…
NSE · CAPLIPOINT.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:01 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Caplin Point Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 21.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Caplin Point Laboratories Limited’s forward annual dividend is ₹8.00 per share, paid semi-annual. The forward yield is 0.34% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Caplin Point Laboratories Limited’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Caplin Point Laboratories Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive product portfolio encompasses a broad spectrum of pharmaceutical dosage forms, including various types of injections (liquid, lyophilized, IV infusions, powder for injection), oral preparations (tablets, liquid orals, capsules, softgel capsules, dry syrups), specialized applications (ophthalmic products, suppositories and ovules), and topical treatments (topicals, dermo cosmetics, inhalers). Beyond manufacturing, the company also manages an e-commerce platform named QueTenX. Established in 1990, Caplin Point Laboratories maintains its headquarters in Chennai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q3 2025 |
|---|
| Feb 7, 2025 |
| ₹18.30 |
| ₹4.93B-3.56% vs estimate |
| Q2 2025 | Nov 7, 2024 | ₹17.20 | ₹4.83B+2.83% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹841.15+₹3.80 (+0.45%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.93% below the high.
₹6,350.50+₹51.50 (+0.82%)
AstraZeneca Pharma India Limited’s quoted price sits in the lower half of its reported 52-week range, 35.52% below the high.
₹798.35+₹3.50 (+0.44%)
Alembic Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 20.01% below the high.
₹924.30-₹21.70 (-2.29%)
Jubilant Pharmova Limited’s quoted price sits in the lower half of its reported 52-week range, 21.87% below the high.
₹782.70-₹4.85 (-0.62%)
NATCO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 36.2% below the high.
₹113.35-₹5.96 (-5.0%)
Morepen Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 24.78% below the high.
₹1,028.30-₹22.80 (-2.17%)
Innova Captab Limited’s quoted price sits in the upper half of its reported 52-week range, 24.03% below the high.
₹179.37-₹5.56 (-3.01%)
IOL Chemicals and Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 19.92% below the high.
